Navitus Drug Trend Report: Keeping Costs Low for Plans and Members in an Era of Accelerating Inflation
MADISON, Wis.--(BUSINESS WIRE)-- Navitus, the nation's first transparent, pass-through pharmacy benefit manager (PBM), released its ninth annual Drug Trend Report today, revealing how commercial plan sponsors saved millions in prescription costs while maintaining high-quality member care. 30% of Navitus clients spent less in 2024 than in the previous year, while overall client book of business drug cost trend was managed to 7%. The data shows that medications such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are creating unprecedented financial pressure on plan sponsors as utilization for diabetes treatment increased 26% year-over-year.
Overall health spending in the United States is nearly $4.9 trillion and projected to increase nearly 6% annually over the next decade. 1 A subset of this, prescription drug spending, was estimated to be $487 billion in 2024, an industry-wide 11.4% increase over the previous year, compared to 7% for Navitus clients. While the industry faces these escalating cost pressures, our latest Drug Trend Report highlights how Navitus continues to outperform industry trends and save clients money in this challenging environment, including companies such as Progressive Insurance.
'Navitus stands out for its commitment to transparency and managing to lowest net cost, which has significantly benefited Progressive and its members. From the outset, their 100% pass-through model has ensured that we receive the full value of manufacturer rebates and discounts, directly translating to reduced pharmacy costs,' said Heidi Minter, Data Analyst, Benefits & Design Services, Progressive Insurance.
The Navitus Drug Trend Report revealed three critical trends influencing the broader industry:
1.
26% increase in GLP-1 RAs use for treatment of type 2 diabetes. While delivering significant clinical benefits, these medications are contributing substantially to pharmaceutical cost increases for benefit plans:
Net trend in the diabetes category increased 8.5%, driven by growth in both the use of GLP-1 RAs, including Ozempic, Mounjaro and Trulicity, and a 16% increase in use of sodium-glucose cotransporter-2 inhibitors (SGLT-2s), including Farxiga and Jardiance.
The prevalence and cost of GLP-1 RAs and SLGT-2s resulted in an overall unit cost increase of 3.0% for the diabetes category, in spite of the net cost decrease of more than 28% for insulin in 2024.
2.
Biosimilars delivered $315 million in savings with a 60% reduction in Humira costs. Targeted immunomodulators (TIMs) treat a wide range of autoimmune disorders, from rheumatoid arthritis and psoriasis to inflammatory bowel diseases. The launch of Humira biosimilar alternatives in 2023 significantly changed the landscape of the category as these clinically-equivalent, much lower cost options were added to formulary. After adding biosimilars to formulary, Navitus took a decisive step to lower costs further by removing Humira from formulary in June 2024. This led to key results including:
Over $315 million in upfront cost savings.
60% reduction in net costs per claim.
3.
Specialty medication utilization increased 12%. Approximately 75% of new drug approvals have been for specialty or medical specialty agents, and that trend is expected to continue in the next two years. Key factors included:
Oncology net trend increased more than 13%, driven by both higher utilization and unit cost: Utilization of newer breast cancer treatments (Kisqali, Verzenio) increased 20%, driving overall cost.
In specialty dermatology, Dupixent (dupilumab) emerged as the most rapidly growing drug of 2024. The category saw a net trend increase of more than 45% and Dupixent represented 96% of category cost and utilization.
While increased use of newer, more expensive agents like Kesimpta created upward pressure within the multiple sclerosis category, generics represented more than 50% of prescriptions filled at 10% of the cost.
Expand
'Our annual Drug Trend Report confirms we were able to control year-over-year costs for commercial clients - both large and small - and deliver savings greater than the estimated industry averages,' said Sharon Faust, PharmD, MBA, CSP, Chief Pharmacy Officer, Navitus Health Solutions. 'Deploying generic-first strategies, facilitating adoption of new biosimilars, ensuring 100% pass-through of negotiated rebates and discounts, and supporting clinically appropriate prescribing, utilization and formulary management remain core to our focus.'
Access the Navitus Drug Trend Report executive summary here: www.navitus.com/DTR2024
Methodology: The Navitus drug trend is calculated by comparing the net total cost per-member per-month (PMPM) for 2024 to that for 2023. Net cost PMPM represents full-year (Q1-Q4) data for total member copays and plan paid amounts minus manufacturer rebates and fees. This value is divided by the total number of members and by 12 months of the year. The data represents employer plan sponsors and health plans. In order to be included organizations must have been with Navitus for two full calendar years.
* Due to varying coverage decisions by clients, GLP-1s for weight loss were not included in the Drug Trend Report, yet they still warrant thoughtful consideration and conversation in the overall picture of trend and future decisions. The DTR only represents prescriptions under the pharmacy benefit. 40% of Rx spend is through the medical benefit and warrants careful consideration by plans.
Sources:
About Navitus
Navitus remains the nation's first transparent, pass-through pharmacy benefit manager (PBM). It uniquely brings clarity to drug pricing and takes costs out of the drug supply chain. Unlike traditional PBMs that generate profit by retaining an undisclosed portion of rebates and discounts negotiated with drug manufacturers and pharmacies, Navitus passes along the complete savings to clients, enabling them to make medication more affordable for their members. Navitus was established more than 20 years ago by Navitus Health Solutions, LLC, a pioneering pharmacy solutions company. The organization delivers a range of services through portfolio brands including Navitus, Lumicera, Archimedes. Owned by SSM Health and Costco, Navitus Health Solutions serves over 18 million lives across 800 clients including employers, unions, government plans, payors and health systems. For more information, please visit www.navitus.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
35 minutes ago
- Buzz Feed
Lizzo Talks About Using Ozempic For Weight Loss
There's no point in stressing out over speculation and rumors regarding Lizzo — she's an open book. On a June 19 episode of the Just Trish podcast, Lizzo admitted that she tried Ozempic and other GLP-1 drugs, which are used to regulate type 2 diabetes and obesity, at one point in her "weight release" journey. Over the years, the "Truth Hurts" singer has been rather forthcoming with her fitness journey, documenting it on social media and sharing her progress with her fanbase. "I tried everything," she told Trisha Paytas. "Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same item." In the podcast, Lizzo shut down critics of Ozempic and GLP-1 drugs, noting that people are not "cheating" by using the products. "It's not easy," Lizzo said. "It's a drug to help somebody with something they're struggling with. I think people... it's their way of being fat phobic when you're telling someone they're cheating." "They tell people they're cheating by getting that weight loss surgery. I heard about that weight loss surgery. That shit sounds very hard actually. A lot people felt like they almost died on the table, and they got so sick after getting the weight loss surgery. That shits not easy." "I feel like people just like to make fun of fat people. Whether you're big or small or got small, they like to make fun of us," she said. Lizzo claimed that she started noticing different results when adding meat back into her diet. "What did it for me is it was not being vegan," she said. "Because when I was vegan, I was consuming a lot of fake meats, I was eating a lot of bread, I was eating a lot of rice and I had to eat a lot of it to stay full." In her opinion, the "fake sugar and weird shit" in processed foods was holding her back, causing her to eat 3,000 to 5,000 calories a day. "When I started actually eating whole foods and eating, like, beef and chicken and fish," she said, "I was actually full and not expanding my stomach by putting a lot of fake things in there that wasn't actually filling me up." "I feel like I worked really, really hard and I was intentional what I did with my body," she added. And that's that! Take that shame somewhere else because Lizzo doesn't play that. Watch the full episode of Lizzo on the Just Trish podcast here.
Yahoo
3 hours ago
- Yahoo
Is This Nature's Ozempic? Dietitians Weigh in on the Metabolic Benefits of This Underrated Supplement
With GLP-1 medications like Ozempic and Wegovy making headlines for their powerful effects on weight loss, it's no surprise people are asking: Can you boost GLP-1 naturally? The answer is yes, and there is compelling research that shows certain foods and supplements support this powerful appetite-regulating hormone. Dietitians are especially excited about one underrated nutrient: prebiotic chicory root fiber. Let's break down what GLP-1 is, how it works, and how your diet and lifestyle can naturally encourage your body to produce more of it. Chicory root fiber is a type of prebiotic fiber known as inulin, naturally found in the chicory plant. It feeds the beneficial bacteria in your gut, which ferment the fiber and produce compounds called short-chain fatty acids (SCFAs). These SCFAs, in turn, help trigger the release of GLP-1, a hormone that regulates appetite control, gut health, and blood sugar balance. Among prebiotic fibers, chicory root has compelling research to show that consuming at least 10 grams per day can lead to measurable improvements in satiety and metabolic health. Glucagon-like peptide-1, or GLP-1, is a hormone made in the gut during digestion. 'It plays a key role in managing blood sugar levels by stimulating the pancreas to release insulin. GLP-1 also slows down the movement of food from the stomach, promoting the feeling of fullness and reducing appetite,' shares dietitian Gisela Belen Bouvier, MBA, RDN, LDN. If your goal is weight loss or weight management, increasing GLP-1 naturally can help reduce hunger cues, making sticking to a calorie deficit that much easier. The popularity of injectable GLP-1 agonist medications like Ozempic has brought attention to this hormone. But the conversation is expanding beyond medication to include food, supplements, and lifestyle strategies that also support your metabolic health. While many whole foods contain prebiotic fiber and are undoubtedly healthy to include in your diet (like bananas, onions, and asparagus), you'd need to eat five bananas, two large onions, or 10 cups of asparagus just to get five grams of the same fiber in chicory root. That's why functional foods or supplements containing chicory root fiber can be a more practical way to meet your daily intake—especially for people on GLP-1 medications who are eating less overall. Clinical trials back this up. For example, one systematic review and meta-analysis found that chicory root fiber significantly reduced body weight with a daily dose of 10 grams. Participants also saw reductions in BMI, fat mass, waist circumference, and body fat percentage. Meaning, you can lose fat and maintain muscle mass on your weight loss journey when you supplement with chicory root fiber. Similarly, in another study, participants consuming 16 grams per day of oligofructose-enriched inulin experienced a significant increase in GLP-1, along with improved hunger and satiety cues, and a 6-percent reduction in calorie intake compared to a placebo. These findings suggest that chicory root fiber isn't just good for your gut—it may also help you eat less, feel fuller, and support sustainable weight loss. But keep in mind, consistently taking the same amount of chicory root fiber is root fiber is generally considered very safe, especially since it supports the body's natural production of GLP-1. The most common side effect may be temporary digestive discomfort, such as bloating or gas, particularly if you add too much fiber too quickly. To minimize side effects, start slow and drink plenty of water to help your body adjust. Even individuals with irritable bowel syndrome (IBS) may tolerate chicory root fiber well at lower doses. Research suggests that up to 10 grams per day of chicory root fiber can be tolerated by people with IBS, especially when introduced gradually. Chicory root fiber is becoming increasingly available in a variety of convenient formats, including gummies, powders, prebiotic drinks, protein bars, and meal replacement shakes. These products make it easier to get a meaningful dose of fiber—especially for people who are already eating less due to GLP-1 medications or want to control their appetite hormones naturally. When choosing a supplement, ideally, choose brands that use ingredients backed by human clinical research, particularly studies that show benefits related to GLP-1 and weight management. For weight loss, remember to consume the clinically significant dose of at least 10 grams of chicory root fiber per day, taken consistently for 8 weeks or more. Products that combine chicory root fiber with other functional ingredients, like protein or low-glycemic carbohydrates, may offer additional support for appetite control, blood sugar balance, and sustained energy levels. While no supplement alone will lead to lasting weight loss, combining chicory root fiber with balanced nutrition and regular movement can naturally support GLP-1 production. Prioritize fiber-rich foods, healthy fats, and slow-digesting carbs, along with functional supplements like chicory root fiber, to increase satiety and support your metabolic This Nature's Ozempic? Dietitians Weigh in on the Metabolic Benefits of This Underrated Supplement first appeared on Men's Journal on Jun 20, 2025
Yahoo
4 hours ago
- Yahoo
The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs
A new weight-loss treatment that can be administered as either a weekly injection or a daily pill has shown promising results in early-stage trials, according to a new study. In one of the trials, 125 adults were assigned to weekly injections of amycretin. Those receiving the 60 milligram dose lost nearly a quarter of their body weight over 36 weeks. This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost 15 per cent of their body weight over a longer 68 week period. Another trial enrolled 144 adults to test the pill version of amycretin. Those who took the 100 milligram daily tablet lost an average of 13.1 percent of their weight over 12 weeks. While jabs like Ozempic, Wegovy and Mounjaro only target the body's GLP-1 receptors, amycretin targets them as well as the amylin receptors, which help regulate blood glucose levels and appetite. The drug helps to prevent overeating and promote feelings of satiety. The findings were published in The Lancet and presented this week at the American Diabetes Association's Scientific Sessions in Chicago. Researchers also reported that the drug appeared to improve participants' blood sugar control, an important marker for those at risk of developing Type 2 diabetes. Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, especially in Britain, where around 1.5 million people currently receive weight-loss treatments, mostly as injections prescribed through specialised clinics or by private providers. Pill formulations may simplify prescribing and make long-term weight-loss support easier to scale up. Unlike drugs like Ozempic, amycretin tablets would not need to be refrigerated and do not require syringes. However, amycretin remains in the early stages of clinical testing and that larger trials will be required to fully establish its safety and efficacy. Both forms of the drug were also associated with improvements in blood sugar levels. Patients did report side effects, including nausea and vomiting, but researchers said that they tended to resolve as the treatment progressed.
